Moderna Business Summary

Moderna, Inc. operates as a commercial-stage biotechnology leader leveraging a proprietary messenger RNA (mRNA) platform to develop a diverse pipeline of vaccines and therapeutics. The company generates the vast majority of its revenue through product sales of its authorized respiratory vaccines, including Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for RSV, while also deriving income from strategic collaborations, licensing fees, and stand-ready manufacturing agreements with global governments. As of early 2026, Moderna is aggressively pivoting its business segments to include oncology—headlined by its individualized neoantigen therapy developed with Merck—and rare disease treatments to offset declining pandemic-era demand. In the competitive landscape, Moderna maintains a frontrunner position in mRNA technology alongside primary rivals Pfizer and BioNTech, while facing intensifying pressure from GSK in the RSV market and Novavax in the protein-based vaccine sector as it transitions toward a sustainable, multi-product commercial model. The company was founded in 2010 by a distinguished group of scientists and entrepreneurs, including Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer. Leadership is currently spearheaded by CEO Stéphane Bancel, a former CEO of BioMérieux known for his high-velocity R&D culture, and President Stephen Hoge, M.D., who oversees the company's scientific strategy. The executive team includes CFO Jamey Mock, Chief Technical Operations and Quality Officer Jerh Collins, and Chief Medical Officer Jacqueline Miller, M.D. (with David Berman, M.D., Ph.D., slated to join as Chief Development Officer in March 2026). Moderna is governed by a board that includes Chairman Noubar Afeyan of Flagship Pioneering and David M. Rubenstein, co-founder of The Carlyle Group. Significant institutional backing is provided by major asset managers including Vanguard Group, BlackRock, and Baillie Gifford, alongside continued strategic support from Flagship Pioneering.